Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

Seasonal Influenza Clinical Trial

Official title:

A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2009-2010, When Administered to Elderly Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00956761
• Other study ID #: V70_09S
• Secondary ID: 2009-010586-23
• Status: Completed
• Phase: Phase 2
• First received: August 8, 2009
• Last updated: December 21, 2015
• Start date: June 2009
• Est. completion date: June 2009

Study information

• Verified date: December 2015
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: EMEA
• Study type: Interventional

Clinical Trial Summary

This is a trial for annual registration of the updated seasonal influenza vaccine formulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: June 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 65 Years and older

Eligibility

Key Inclusion Criteria:

• Subjects of 65 years of age or older

• Mentally competent

• Willing and able to give written informed consent prior to study entry

• Able to comply with all the study requirements

• In general good health

Key Exclusion Criteria:

• Any serious chronic or acute disease disease

• History of any anaphylactic reaction and/or serious allergic reaction following a vaccination

• A proven hypersensitivity to any component of the study vaccine

• Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age)

• Bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject

• Within the past 12 months, participants had received more than one injection of influenza vaccine

• Within the past 6 months, participants had laboratory confirmed influenza disease or received influenza vaccine

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza, Human
• Seasonal Influenza

Intervention

Biological:
• Seasonal Influenza Vaccine (MF59C.1)
1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010

Locations

Country	Name	City	State
Italy	Site 2: Ufficio Igiene e Sanità Pubblica di Lanciano, ASL Lanciano - Vasto, sede legale Via S. Spaventa, 37	Lanciano
Italy	Site 3: Pianiga Distretto n. 2 - Area Sud - Azienda ULSS 13 Mirano-Via Nazionale 48	Pianiga

Sponsors (2)

Lead Sponsor	Collaborator
Novartis	Novartis Vaccines

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One Vaccination of FLUAD	Immunogenicity was measured as the percentage of participants who achieved seroconversion or significant increase in single radial hemolysis (SRH) area, against each of the three vaccine strains, three weeks after vaccination (day 21), evaluated using SRH assay.; Seroconversion: proportion of participants with negative pre-vaccination serum and a post-vaccination serum area = 25 mm2. Significant increase: proportion of participants with at least a 50% increase in area from positive pre-vaccination serum. Seroconversion or significant increase: proportion of participants with either seroconversion or significant increase.; The European (Committee for Medicinal Products for Human Use [CHMP]) criterion is met, if percentage of participants achieving seroconversion or significant increase in SRH area is 30% (=65 years).	Day 21	No
Primary	Geometric Mean Ratio of Participants Against Each of the Three Vaccine Strains After One Vaccination of FLUAD	Geometric mean ratio (GMR) of participants was calculated as the ratio of post-vaccination to pre-vaccination SRH geometric mean areas (GMAs), directed against each of the three vaccine strains, three weeks after FLUAD vaccination (day 21).; The CHMP criterion was met if the geometric mean increase (GMR, day 21/day 0) in SRH antibody area is >2.0 (=65 years).	day 21	No
Primary	Percentage of Participants Who Achieved SRH Area =25mm2 Against Each of the Three Vaccine Strains After One Vaccination of FLUAD	Immunogenicity was measured as the percentage of participants achieving SRH area =25 mm2 against each of the three vaccine strains at baseline (day 0) and three weeks after FLUAD vaccination (day 21).; This criterion is met according to CHMP guideline if percentage of participants achieving SRH area =25 mm2 is 60% (=65 years).	day 21	No
Primary	Number of Participants Who Reported Solicited Local and Systemic Reactions	Safety was assessed for participants who reported solicited local and systemic reactions from day 0 up to and including day 3 after the FLUAD vaccination.	0-3 days post-vaccination	Yes